Injection of Lymphocytes From Haplo-identical Donor Following Chemotherapy in Patients With High-risk Acute Myeloblastic Leukemia Not Eligible for an Allogeneic Hematopoietic Stem Cell Transplantation

NCT04886206 | Unknown Phase 1

• 1 other identifier: RC20_0357
• Study Type: interventional
• Target: 12
• Locations: 1 country
• Sites: 1

Brief Summary

Patients with high risk AML non eligible for an intensive treatment and for an allogeneic transplantation will be treated with azacitidine and venetoclax. The fourth, fifth and sixth injection of azacitidine will be followed by injection of haplo-identical lymphocytes (HLI). This is a single-center phase I study to identify the dose of HLI with the most tolerable toxicity. TheBayesian continuous reassessment method (CRM) will be used

Conditions

Acute Myeloid Leukemia (AML)

Outcome Measures

Primary Outcomes (1)

• number of DLT

  by day 14

Secondary Outcomes (3)

• cumulative incidence of relapse

  1 YEAR

• relapse-free survival

  1 YEAR

• overall survival

  1 YEAR

Interventions

DLI BIOLOGICAL

the patients will receive the injection of donor lymphocytes from haplo-identical donor (the son or daughter or possibly nephew or niece of the patient). No immunosuppressive drugs will be used. The HLI dose levels are 1) 1x107 CD3+/kg 2) 5x107 CD3+/kg 3) 7.5x107 CD3+/kg 4) 1x108 CD3+/kg.The CRM method (Continual Reassessment Method) was chosen to specify the dose of cells to be injected, each patient being assigned a dose that is believed to be associated with the target toxicity corresponding to the maximum tolerated dose (MTD). The dose-toxicity curve will be readjusted after assessing the toxicity of each patient.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• age ≥18 years
• patients with de novo or secondary AML, with an unfavorable or intermediate karyotype (according to the 2017 ELN classification), or patients with relapsing AML who may receive second-line treatment
• not candidates for intensive induction, for the following reasons
• years or ≥ 18 to 74 years and at least one of the following comorbidities: PS ≥ 2 or a history of heart failure requiring treatment or LVEF ≤ 50% or chronic stable angina or FEV1 ≤ 65% or DLCO ≤ 65% or creatinine clearance \<45 ml / min; or liver damage with total bilirubin\> 1.5 N or other comorbidities that the hematologist considers incompatible with intensive treatment
• ineligible for a classic allogeneic hematopoietic stem cell transplant due to the presence of co-morbidities or too high a risk of toxicity \>70 years old or at least one of the following comorbidities: PS ≥ 2 or a history of heart failure requiring treatment or LVEF ≤ 50% or chronic stable angina or FEV1 ≤ 65% or DLCO ≤ 65% or creatinine clearance \<45 ml / min; or liver damage with total bilirubin\> 1.5 N
• may receive chemotherapy with hypomethylating agents have a partially compatible (haplo-identical) major family donor (≥18 years old) eligible for lymphocyte donation.

You may not qualify if:

• AML with favorable karyotype (according to ELN 2017) in RC1
• Patient with refractory or progressive AML
• Other progressive cancer in progress
• Karnosky index \<60% or PS\> 2
• Severe hepatic function disturbance: transaminases\> 5 N, hyperbilirubinemia\> 30 µm / L
• Severe infection requiring hospitalization.
• Psychiatric illness compromising the understanding of the information or the carrying out of the study.
• woman of childbearing potential and refusing an effective method of contraception.
• Minor
• Adult under tutorship or curatorship, under legal protection or under family authorization
• Minor family donor (\<18 years old)

Sponsors & Collaborators

• Nantes University Hospital: lead

Study Sites (1)

CHU de Nantes

Nantes, 44000, France

RECRUITING

MeSH Terms

Conditions

Leukemia, Myeloid, Acute

Condition Hierarchy (Ancestors)

Leukemia, Myeloid; Leukemia; Neoplasms by Histologic Type; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases

Study Officials

• Thierry Guillaume

  Nantes University Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Thierry Guillaume

CONTACT

02 40 08 49 45; thierry.guillaume@chu-nantes.fr

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: Continual Reassessment Method for MTD

Study Record Dates

• First Submitted: May 10, 2021
• First Posted: May 13, 2021
• Study Start: November 10, 2021
• Primary Completion: November 1, 2024
• Study Completion: November 1, 2024
• Last Updated: May 11, 2022

Record last verified: 2022-05

Locations

FR (1)